The first peptide polyagonist that was officially approved for T2DM and obesity was tirzepatide (LY3298176), a dual GLP-1/GIP receptor agonist which is currently under investigation in RCTs for obesity and NAFLD [7]. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.